Marta Martins

Dr. Marta Martins

Instituto de Medicina Molecular João Lobo Antunes, Lisbon, Lisboa, Portugal
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2012 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MOMichael J. Ombrello
Michael J. Ombrello
ERElaine F. Remmers
Elaine F. Remmers
GSGuangping Sun
Guangping Sun
AFAlexandra F. Freeman
Alexandra F. Freeman
SDShrimati Datta
Shrimati Datta
JMJoshua D. Milner
Joshua D. Milner
Mendelian analysis of disorders of immune regulation can provide insight into molecular pathways associated with host defense and immune tolerance. We identified three families with a dominantly inherited complex of cold-induced urticaria, antibody deficiency, and susceptibility to infection and autoimmunity. Immunophenotyping methods included flow cytometry, analysis of serum immunoglobulins and autoantibodies, lymphocyte stimulation, and enzymatic assays. Genetic studies included linkage analysis, targeted Sanger sequencing, and next-generation whole-genome sequencing. Cold urticaria occurred in all affected subjects. Other, variable manifestations included atopy, granulomatous rash, autoimmune thyroiditis, the presence of antinuclear antibodies, sinopulmonary infections, and common variable immunodeficiency. Levels of serum IgM and IgA and circulating natural killer cells and class-switched memory B cells were reduced. Linkage analysis showed a 7-Mb candidate interval on chromosome 16q in one family, overlapping by 3.5 Mb a disease-associated haplotype in a smaller family. This interval includes PLCG2, encoding phospholipase Cγ2 (PLCγ2), a signaling molecule expressed in B cells, natural killer cells, and mast cells. Sequencing of complementary DNA revealed heterozygous transcripts lacking exon 19 in two families and lacking exons 20 through 22 in a third family. Genomic sequencing identified three distinct in-frame deletions that cosegregated with disease. These deletions, located within a region encoding an autoinhibitory domain, result in protein products with constitutive phospholipase activity. PLCG2-expressing cells had diminished cellular signaling at 37°C but enhanced signaling at subphysiologic temperatures. Genomic deletions in PLCG2 cause gain of PLCγ2 function, leading to signaling abnormalities in multiple leukocyte subsets and a phenotype encompassing both excessive and deficient immune function. (Funded by the National Institutes of Health Intramural Research Programs and others.)

1 October 2012 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
QZQing Zhou
Qing Zhou
GLGeun-Shik Lee
Geun-Shik Lee
JBJillian Brady
Jillian Brady
SDShrimati Datta
Shrimati Datta
MKMatilda Katan
Matilda Katan
IAIvona Aksentijevich
Ivona Aksentijevich

2 February 2019 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
LMLorenza Magno
Lorenza Magno
CLChristian B. Lessard
Christian B. Lessard
MMMarta Martins
Marta Martins
VLVerena Lang
Verena Lang
PCPedro Cruz
Pedro Cruz
PWpaul whiting
paul whiting
Recent Genome Wide Association Studies (GWAS) have identified novel rare coding variants in immune genes associated with late onset Alzheimer’s disease (LOAD). Amongst these, a polymorphism in phospholipase C-gamma 2 (PLCG2) P522R has been reported to be protective against LOAD. PLC enzymes are key elements in signal transmission networks and are potentially druggable targets. PLCG2 is highly expressed in the hematopoietic system. Hypermorphic mutations in PLCG2 in humans have been reported to cause autoinflammation and immune disorders, suggesting a key role for this enzyme in the regulation of immune cell function. We assessed PLCG2 distribution in human and mouse brain tissue via immunohistochemistry and in situ hybridization. We transfected heterologous cell systems (COS7 and HEK293T cells) to determine the effect of the P522R AD-associated variant on enzymatic function using various orthogonal assays, including a radioactive assay, IP-One ELISA, and calcium assays. PLCG2 expression is restricted primarily to microglia and granule cells of the dentate gyrus. Plcg2 mRNA is maintained in plaque-associated microglia in the cerebral tissue of an AD mouse model. Functional analysis of the p.P522R variant demonstrated a small hypermorphic effect of the mutation on enzyme function. The PLCG2 P522R variant is protective against AD. We show that PLCG2 is expressed in brain microglia, and the p.P522R polymorphism weakly increases enzyme function. These data suggest that activation of PLCγ2 and not inhibition could be therapeutically beneficial in AD. PLCγ2 is therefore a potential target for modulating microglia function in AD, and a small molecule drug that weakly activates PLCγ2 may be one potential therapeutic approach.

14 December 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JNJoão Farela Neves
João Farela Neves
RDRainer Doffinger
Rainer Doffinger
GBGabriela Barcena-Morales
Gabriela Barcena-Morales
CMCatarina Gregório Martins
Catarina Gregório Martins
OPOlivier Papapietro
Olivier Papapietro
SNSergey Nejentsev
Sergey Nejentsev
Background: The auto-inflammation and phospholipase Cγ2 (PLCγ2)-associated antibody deficiency and immune dysregulation (APLAID) syndrome is a rare primary immunodeficiency caused by a gain-of-function mutation S707Y in the PLCG2 gene previously described in two patients from one family. The APLAID patients presented with early-onset blistering skin lesions, posterior uveitis, inflammatory bowel disease (IBD) and recurrent sinopulmonary infections caused by a humoral defect, but lacked circulating autoantibodies and had no cold-induced urticaria, contrary to the patients with the related PLAID syndrome. Case: We describe a new APLAID patient who presented with vesiculopustular rash in the 1st weeks of life, followed by IBD, posterior uveitis, recurrent chest infections, interstitial pneumonitis, and also had sensorineural deafness and cutis laxa. Her disease has been refractory to most treatments, including IL1 blockers and a trial with ruxolitinib has been attempted. Results: In this patient, we found a unique de novo heterozygous missense L848P mutation in the PLCG2 gene, predicted to affect the PLCγ2 structure. Similarly to S707Y, the L848P mutation led to the increased basal and EGF-stimulated PLCγ2 activity in vitro. Whole blood assays showed reduced production of IFN-γ and IL-17 in response to polyclonal T-cell stimulation and reduced production of IL-10 and IL-1β after LPS stimulation. Reduced IL-1β levels and the lack of clinical response to treatment with IL-1 blockers argue against NLRP3 inflammasome hyperactivation being the main mechanism mediating the APLAID pathogenesis. Conclusion: Our findings indicate that L848P is novel a gain-of-function mutation that leads to PLCγ2 activation and suggest cutis laxa as a possible clinical manifestations of the APLAID syndrome.

1 December 2012 in Structure
Verified
Journal Article
Open access
TBTom D. Bunney
Tom D. Bunney
DEDiego Esposito
Diego Esposito
CMCorine Mas-Droux
Corine Mas-Droux
ELEkatarina Lamber
Ekatarina Lamber
RBRhona W. Baxendale
Rhona W. Baxendale
MKMatilda Katan
Matilda Katan
Multidomain proteins incorporating interaction domains are central to regulation of cellular processes. The elucidation of structural organization and mechanistic insights into many of these proteins, however, remain challenging due to their inherent flexibility. Here, we describe the organization and function of four interaction domains in PLCγ1 using a combination of structural biology and biochemical approaches. Intramolecular interactions within the regulatory region center on the cSH2 domain, the only domain that also interacts with the PLC-core. In the context of fibroblast growth-factor receptor signaling, the coordinated involvement of nSH2 and cSH2 domains mediates efficient phosphorylation of PLCγ1 resulting in the interruption of an autoinhibitory interface by direct competition and, independently, dissociation of PLCγ1 from the receptor. Further structural insights into the autoinhibitory surfaces provide a framework to interpret gain-of-function mutations in PLCγ isoforms linked to immune disorders and illustrate a distinct mechanism for regulation of PLC activity by common interaction domains.

3 March 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MMMarta Martins
Marta Martins
AMAfshan McCarthy
Afshan McCarthy
RBRhona Baxendale
Rhona Baxendale
SGSabrina Guichard
Sabrina Guichard
LMLorenza Magno
Lorenza Magno
MKMatilda Katan
Matilda Katan
Phospholipase Cε (PLCε) has been characterized as a direct effector of Ras in vitro and in cellular systems; however, the role of PLCε in tumorigenesis and its link to Ras in this context remain unclear. To assess the role of PLCε in Ras-driven cancers, we generated two new mouse strains: one carrying a targeted deletion of Plce (Plce−/−) and the other carrying mutant alleles of Plce unable to bind to Ras (PlceRAm/RAm). The Plce−/− and, to a lesser degree, PlceRAm/RAm transgenic mice exhibited increased susceptibility to tumor formation in the two-stage skin carcinogenesis protocol, revealing a tumor suppressor function for this PLC. This result also suggests that in this context Ras binding in part regulates functions of PLCε. Although significant differences were not seen in the LSL-KrasG12D nonsmall cell lung carcinoma model, down-regulation of PLCε was found in animal tumors and in cellular systems following expression of the oncogenic Ras. An inhibitory impact of PLCε on cell growth requires intact lipase activity and is likely mediated by protein kinase C enzymes. Further cellular studies suggest involvement of histone deacetylase in the mechanism of PLCε down-regulation. Taken together, our results show a previously unidentified tumor suppressor role for this PLC in animal models and, together with observations of marked down-regulation in colorectal, lung, and skin tumors, suggest its use as a biological marker in cancer. Significance Ras oncogens have been implicated in high proportion of cancers. However, selective treatment for Ras oncogenes is not yet available and components that could mediate Ras functions are being extensively assessed as alternative targets. For some potential targets, such as phospholipase Cε (PLCε), it is not clear how they contribute to tumor development. Here we provide several lines of experimental evidence that support a tumor suppressor function of PLCε, contrasting a positive role of several other well-defined effectors of Ras. Our results show a tumor suppressor role for this PLC in animal models and describe its impact on cell proliferation. Together with observations of marked down-regulation in several types of tumors, this study suggests its use as a biological marker in cancer.